{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":13,"description":"Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.\n\ncetuximab: given IV","id":"EG000","otherNumAffected":0,"otherNumAtRisk":13,"seriousNumAffected":0,"seriousNumAtRisk":13,"title":"Arm I (Treatment)"},{"deathsNumAffected":0,"deathsNumAtRisk":6,"description":"Patients receive regular follow-up care","id":"EG001","otherNumAffected":0,"otherNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"title":"Arm II (Control)"}],"frequencyThreshold":"0"}